Loading...
Oncology Pipeline Progress And FAP Targeting Are Expected To Drive Long Term Upside
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
1Y
35.4%7D
-15.6%1Y
35.4%7D
-15.6%You can edit this narrative until Dec 11 11:10 PM. Then, changes will post as Updates.